Abstract: 【Abstract】Cardiovascular disease (CVD) is a common complication in chronic kidney disease (CKD) patients and the main cause of death in patients with end-stage renal disease. Early identification and intervention of CVD is therefore essential to CKD patients. The two cardiac biomarkers, B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), have been used to diagnose heart failure and to assess the severity and prognosis of CVD. However, CKD itself and dialysis treatment often affect serum levels of BNP/NT-proBNP and thus the usefulness of BNP/NT-proBNP in the diagnosis of heart failure and the assessment of severity and prognosis of CVD in CKD patients. This review analyzes the serum levels of BNP/NT-proBNP and their influencing factors in CKD patients through a survey of BNP/NT-proBNP, and briefly discusses the application prospects of BNP/NT-proBNP in CKD patients with CVD.

Key words: Chronic kidney disease, Cardiovascular disease, B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide